Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.
The company was incorporated in 2018 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 322 |
| CEO | Christopher Peetz |
Contact Details
Address: 950 Tower Lane, Suite 1050 Foster City, California 94404 United States | |
| Phone | 650 667 4085 |
| Website | mirumpharma.com |
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| Employer ID | 83-1281555 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer and Director |
| Peter Radovich M.B.A., Ph.D. | Chief Operating Officer and President |
| Eric H. Bjerkholt M.B.A. | Chief Financial Officer |
| Dr. Joanne M. J. Quan M.D. | Chief Medical Officer |
| Dr. Jean-Luc Girardet Ph.D. | Chief Technical Officer |
| Dr. Pamela Vig Ph.D. | Chief Scientific Officer |
| Andrew McKibben | Senior Vice President, Strategic Finance and Investor Relations |
| Paul K. Ross | Chief Compliance Officer |
| Douglas T. Sheehy J.D. | Chief Legal Officer |
| Erin Campany | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | 144 | Filing |
| Jun 6, 2025 | SCHEDULE 13G/A | Filing |
| Jun 3, 2025 | 144 | Filing |
| Jun 2, 2025 | 144 | Filing |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| May 7, 2025 | SCHEDULE 13G/A | Filing |